Merdury Biopharmaceutical Corporation

NT$5.14As of Sun 8 Nov 2026, 12:00 UTC
TPEx:6932Healthcare
Country Taiwan
PE (Fwd) •••
TSR 4Y CAGR (15.56%)
Div yield —
ROE (22.78%)
Drug Manufacturers (Specialty & Generic)
Beta (5Y) (1.02)
PE TTM —
TSR TTM (27.50%)
Mkt cap NT$2.198B
ROIC (12.12%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
NT$5.11
(0.52%)
(63.56%)
Hold 7|2|12|4|8
4Q25
1Q26
2Q26
3Q26
Earnings per shareNT$
0.06
0.07
0.07
0.07
15.35%
31.22%
17.97%
14.02%
RevenueNT$M
140.8
147.2
150.9
149.9
1.03%
4.05%
4.97%
7.03%
Peers (US$67.04M)
Cap (US$)
PE
59.32M
22.19x
Capital
TTM
5Y
10Y
Leveragex
2.055
2.494
2.018
EBIT/Intx
0.608
0.114
0.119
Own earn%
219.01
(99.38)
(91.71)
Sh yield%
56.69
19.83
20.75
Owners
Insiders/Inst%
4.92
47.46
Short interest%
2.31
SBC / revenue%
1.56
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
7
Op margin range%
18–25
$1 testx
—
Incr. ROIC%
0